REGENXBIO to Participate in Upcoming Investor Conferences

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in two investor conferences. The first is the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, at 9:10 a.m. ET in New York, NY. The second event is the BofA Securities 2022 Virtual Biotech SMID Cap Conference, with a fireside chat on December 8, 2022, at 10:50 a.m. ET. Live webcasts can be accessed on REGENXBIO's website, with replays available for 30 days. The company is a leader in gene therapy, focusing on advancing its 5x'25 strategy to develop five AAV Therapeutics by 2025.

ROCKVILLE, Md., Nov. 22, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:

Piper Sandler 34th Annual Healthcare Conference
Presentation Date: Thursday, December 1, 2022
Presentation Time: 9:10 a.m. ET
Location: Lotte New York Palace, New York, NY

BofA Securities 2022 Virtual Biotech SMID Cap Conference
Fireside Chat Date: Thursday, December 8, 2022
Fireside Chat Time: 10:50 a.m. ET

Live webcasts of the presentations can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcasts will be available for approximately 30 days following the presentation.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.

Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301684731.html

SOURCE REGENXBIO Inc.

FAQ

What conferences will REGENXBIO participate in December 2022?

REGENXBIO will participate in the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, and the BofA Securities 2022 Virtual Biotech SMID Cap Conference on December 8, 2022.

When is REGENXBIO's presentation at the Piper Sandler conference?

REGENXBIO's presentation at the Piper Sandler conference is scheduled for December 1, 2022, at 9:10 a.m. ET.

When will the BofA Securities conference fireside chat occur?

The BofA Securities conference fireside chat will take place on December 8, 2022, at 10:50 a.m. ET.

How can I access REGENXBIO's conference presentations?

Live webcasts of REGENXBIO's presentations can be accessed on the Investors section of their website, with archived replays available for approximately 30 days.

What is REGENXBIO's 5x'25 strategy?

REGENXBIO's 5x'25 strategy aims to progress five AAV Therapeutics from its internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.